KR20250122537A - 항-cd24 조성물 및 이의 용도 - Google Patents

항-cd24 조성물 및 이의 용도

Info

Publication number
KR20250122537A
KR20250122537A KR1020257026199A KR20257026199A KR20250122537A KR 20250122537 A KR20250122537 A KR 20250122537A KR 1020257026199 A KR1020257026199 A KR 1020257026199A KR 20257026199 A KR20257026199 A KR 20257026199A KR 20250122537 A KR20250122537 A KR 20250122537A
Authority
KR
South Korea
Prior art keywords
ser
val
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257026199A
Other languages
English (en)
Korean (ko)
Inventor
양 리우
판 쩡
론다 프로레스
헝-엔 초우
즈홍 슈에
페이잉 예
마틴 데븐포트
Original Assignee
온코씨4, 아이앤씨.
칠드런스 내셔널 메디컬 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코씨4, 아이앤씨., 칠드런스 내셔널 메디컬 센터 filed Critical 온코씨4, 아이앤씨.
Publication of KR20250122537A publication Critical patent/KR20250122537A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020257026199A 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도 Pending KR20250122537A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671193P 2018-05-14 2018-05-14
US62/671,193 2018-05-14
KR1020207033131A KR102844265B1 (ko) 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도
PCT/US2019/031983 WO2019222082A1 (en) 2018-05-14 2019-05-13 Anti-cd24 compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033131A Division KR102844265B1 (ko) 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20250122537A true KR20250122537A (ko) 2025-08-13

Family

ID=68540727

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257026199A Pending KR20250122537A (ko) 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도
KR1020207033131A Active KR102844265B1 (ko) 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207033131A Active KR102844265B1 (ko) 2018-05-14 2019-05-13 항-cd24 조성물 및 이의 용도

Country Status (13)

Country Link
US (3) US12286485B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813877A4 (cg-RX-API-DMAC7.html)
JP (2) JP7294758B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250122537A (cg-RX-API-DMAC7.html)
CN (2) CN116589582A (cg-RX-API-DMAC7.html)
AU (2) AU2019269361C1 (cg-RX-API-DMAC7.html)
EA (1) EA202092306A1 (cg-RX-API-DMAC7.html)
IL (1) IL278689B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020012091A (cg-RX-API-DMAC7.html)
SG (1) SG11202010589YA (cg-RX-API-DMAC7.html)
TW (1) TWI835794B (cg-RX-API-DMAC7.html)
WO (1) WO2019222082A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006647B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
JP2022538870A (ja) * 2019-06-25 2022-09-06 イチロフ テック リミテッド 抗cd24抗体及びその使用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR20230143177A (ko) * 2021-02-08 2023-10-11 안텐진 바이올로직스 리미티드 신규한 항-cd24 항체
WO2022178163A2 (en) * 2021-02-18 2022-08-25 Health Research, Inc. Antibody-derived t cell activating technologies
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023280042A1 (zh) * 2021-07-06 2023-01-12 盛禾(中国)生物制药有限公司 一种抗cd24抗体及其应用
CN118076625A (zh) * 2021-09-28 2024-05-24 广州昂科免疫生物技术有限公司 包含071核心肽的融合蛋白及其用途
CN113831412B (zh) * 2021-10-13 2023-06-20 宜明昂科生物医药技术(上海)股份有限公司 靶向cd24的抗体及其制备和用途
CN118369340A (zh) * 2021-11-25 2024-07-19 盛禾(中国)生物制药有限公司 一种双特异性抗原结合蛋白
AU2022404358A1 (en) * 2021-12-07 2024-07-04 Beijing Kanghong Biomedical Co., Ltd Anti-cd24 antibody and use thereof
AU2023258034A1 (en) * 2022-04-20 2024-11-07 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer
CN115947855B (zh) * 2022-05-20 2023-10-27 杭州邦顺制药有限公司 抗cd24抗体的制备及其用途
AU2023320486A1 (en) * 2022-08-04 2025-02-20 Memorial Hospital For Cancer And Allied Diseases Anti-cd24 antibodies and uses thereof
JP2025535498A (ja) * 2022-10-27 2025-10-24 ベイジン ネオエックス バイオテック リミテッド Cd24に対する抗体およびその使用
CN120112561A (zh) * 2022-11-01 2025-06-06 南京昂科免疫生物医药有限公司 一种cd24结合蛋白及其用途
CN115960243B (zh) * 2023-01-09 2025-05-06 中国药科大学 靶向cd24和cd3的双特异性抗体及其应用
CN121311506A (zh) * 2023-06-09 2026-01-09 天境生物科技(上海)有限公司 抗-cd24抗体及其用途
EP4790070A1 (en) * 2023-10-04 2026-08-12 Daegu Gyeongbuk Institute of Science and Technology Anti-cd24 antibody or antigen-binding fragment thereof, and use thereof
WO2025077809A1 (zh) * 2023-10-12 2025-04-17 江苏融泰生物技术有限公司 抗体融合蛋白及应用
WO2025085805A1 (en) * 2023-10-20 2025-04-24 OncoC4, Inc. Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof
TW202535944A (zh) * 2023-11-08 2025-09-16 美商飛斯特醫療公司 Cd24抗體
WO2025151423A1 (en) * 2024-01-08 2025-07-17 OncoC4, Inc. Anti-cd24 antibody drug conjugates and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
CN1894413A (zh) 2003-03-26 2007-01-10 特鲁比昂药品公司 识别cd3或4-1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2009063461A1 (en) 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
EP2574627A1 (en) * 2011-09-30 2013-04-03 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Particular uses of CD24 inhibitors
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN103819561A (zh) 2014-01-22 2014-05-28 中国药科大学 抗cd24单克隆抗体、其可变区序列及其应用
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US9804170B2 (en) * 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
CN105505869A (zh) * 2015-12-21 2016-04-20 河南大学淮河医院 一种针对肿瘤干细胞的嵌合抗原受体t细胞
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1

Also Published As

Publication number Publication date
ZA202006647B (en) 2022-01-26
JP7294758B2 (ja) 2023-06-20
JP7662707B2 (ja) 2025-04-15
EP3813877A1 (en) 2021-05-05
CN116589582A (zh) 2023-08-15
SG11202010589YA (en) 2020-11-27
JP2023123502A (ja) 2023-09-05
US12286485B2 (en) 2025-04-29
EP3813877A4 (en) 2022-05-11
AU2019269361B2 (en) 2025-02-06
MX2024015039A (es) 2025-01-09
CN112424441B (zh) 2023-05-09
JP2021526509A (ja) 2021-10-07
TWI835794B (zh) 2024-03-21
MX2020012091A (es) 2021-04-28
KR20210008487A (ko) 2021-01-22
TW202012434A (zh) 2020-04-01
US20250333532A1 (en) 2025-10-30
CA3099554A1 (en) 2019-11-21
KR102844265B1 (ko) 2025-08-13
IL278689A (cg-RX-API-DMAC7.html) 2020-12-31
WO2019222082A1 (en) 2019-11-21
US20210214458A1 (en) 2021-07-15
AU2025201864A1 (en) 2025-04-03
MX2025002661A (es) 2025-04-02
US20250243292A1 (en) 2025-07-31
IL278689B1 (en) 2026-01-01
NZ769355A (en) 2025-03-28
AU2019269361A1 (en) 2020-11-19
AU2019269361C1 (en) 2025-06-12
IL278689B2 (en) 2026-05-01
CN112424441A (zh) 2021-02-26
BR112020022482A2 (pt) 2021-02-09
EA202092306A1 (ru) 2021-02-19

Similar Documents

Publication Publication Date Title
KR102844265B1 (ko) 항-cd24 조성물 및 이의 용도
US20240052044A1 (en) Non-blocking human ccr8 binders
RU2762704C2 (ru) Новое psma-связывающее антитело и его применения
JP7225135B2 (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
US20220323600A1 (en) Teac and attac immunooncology compositions and methods
TWI884911B (zh) 具有改良之免疫療效但減弱之副作用之突變抗ctla-4抗體
US20240052045A1 (en) Murine cross-reactive human ccr8 binders
JP2022513729A (ja) ヒト化及び親和性成熟抗ceacam1抗体
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
US20250195645A1 (en) Combination of multispecific molecule and immune checkpoint inhibitor
EA045813B1 (ru) Анти-cd24 композиции и их применения
EA052120B1 (ru) Анти-cd24 композиции и их применения
EP4613774A1 (en) Single domain antibody targeting human ror1
BR122025008367A2 (pt) Uso de um anticorpo anti-cd24 para reduzir o crescimento de um câncer
BR122025008367B1 (pt) Uso de um anticorpo anti-cd24 para reduzir o crescimento de um câncer
WO2025085805A1 (en) Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof
HK40115416A (en) Combination of multi-specific molecule and immune checkpoint inhibitor
HK40018012A (en) Compounds and methods for tumour-specific cell depletion

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R15-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000